There were 148 press releases posted in the last 24 hours and 155,070 in the last 365 days.

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy.

/EIN News/ -- For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit.

For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study exploring the LUNAR assay’s ability to identify early-stage colorectal cancer patients who may benefit from adjuvant therapy after undergoing an intervention with curative intent (Abstract 3602). This is a particularly challenging clinical setting for the detection of circulating tumor DNA in blood because patients who have undergone curative-intent interventions typically have little-to-no evidence of disease, and very low residual tumor DNA shedding in circulation.

“Guardant is committed to expanding the benefits of precision oncology across the continuum of care,” said Guardant Health Chief Medical Officer Dr. Richard Lanman. “The new insights we and our research partners will bring to ASCO this year continue to demonstrate the many advantages of blood-based genomic testing over tissue-based genomic testing in support of a blood-first paradigm in early stage and late stage cancer.”

Guardant’s data will be featured in the following presentations at ASCO this year:

Abstract Title Date Time Abstract Number
Analytical validation of a tumor-agnostic integrated multi-analyte
circulating tumor DNA (ctDNA) assay in early stage cancer
6/1
 
8 a.m. - 11 a.m. 3057
Dynamic monitoring of circulating tumor DNA next-generation gene
sequencing as a predictive biomarker of response and progression free
survival after pembrolizumab monotherapy in patients with advanced NSCLC.
6/1

 
8 a.m. - 11 a.m. 3040
Molecular biology and treatment strategies for non-V600 BRAF-mutant
NSCLC
6/1
 
8 a.m. - 11 a.m. 3102
Molecular circulating tumor DNA response to identify long-term survival in
patients receiving immunotherapy with initial radiologic stable disease
6/1
 
8 a.m. - 11 a.m. 2546
Comprehensive genomic profiling of circulating cell-free DNA (cfDNA)
distinguishes focal amplification (amp) from aneuploidy among MET amps
in diverse advanced cancer types
6/1

 
8 a.m. - 11 a.m. 3046
Baseline cfDNA characteristics and evolution of cfDNA profile during
treatment with selective FGFR inhibitor TAS-120
6/1  8 a.m. - 11 a.m. 3056
 
Identification of genomic alterations by circulating tumor DNA in
leiomyosarcoma: A molecular analysis of 73 patients
6/1
 
8 a.m. - 11 a.m. 11044
TiFFANY study: A multicenter phase II basket-type clinical trial to evaluate
efficacy and safety of pan-FGFR inhibitor TAS-120 for advanced solid
malignancies with FGFR alterations identified by circulating tumor DNA
6/1

 
8 a.m. - 11 a.m. TPS3156
Profiling of genomic alterations in MAPK/ERK signaling in a large cohort of
metastatic prostate cancer (mPC) patients
6/1
 
1:15 p.m. - 4:15 p.m. 5032
Genomic landscape of metastatic hormone sensitive prostate cancer
(mHSPC) vs. metastatic castration-refractory prostate cancer (mCRPC) by
circulating tumor DNA (ctDNA).
6/1

 
1:15 p.m. - 4:15 p.m 5043
AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic
castration-resistant prostate cancer (mCRPC) treated with high-dose
testosterone.
6/1

 
1:15 p.m. - 4:15 p.m 5058
Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive
biomarkers of survival in MYSTIC: First-line durvalumab (D) ±
tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC.
6/2

 
8 a.m. - 11 a.m. 9016
Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib
in patients (pts) with advanced ALK-positive non-small cell lung cancer
(NSCLC)
6/2

 
8 a.m. - 11 a.m. 9019
Longitudinal Analysis of Plasma ALK Mutations During Treatment with
Next-Generation ALK Inhibitors.
6/2
 
8 a.m. - 11 a.m. 9068
Tracking plasma KRAS mutations (m) in lung adenocarcinoma (LUAC)
patients (p)
6/2
 
8 a.m. - 11 a.m. 9055
A plasma-only integrated somatic and epigenomic circulating tumor DNA
(ctDNA) assay to inform recurrence risk in colorectal cancer (CRC).
6/3
 
8 a.m. - 11 a.m. 3602
Updated analysis and impact of plasma-detected microsatellite stability
(MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab
(D) plus tremelimumab (T) and best supportive care (BSC) versus BSC
alone in patients (pts) with refractory metastatic colorectal carcinoma
(rmCRC)
6/3

 
8 a.m. - 11 a.m.

 
3512
Blood-Based Genomic Profiling of cell-free DNA (OMNI) to Identify
Microsatellite Instability, tumor mutational burden and Wnt/B-Catenin
Pathway Alterations in Patients with Gastrointestinal Tract Cancers
6/3

 
8 a.m. - 11 a.m.

 
3552
Identifying anti-EGFR (EGFRi) response subgroups using evidence of ctDNA
selective pressure
6/3
 
8 a.m. - 11 a.m. 3587
Genomic alterations after EGFR blockade in patients with RAS wild-type
metastatic colorectal cancer: Combined tissue and blood-based analysis
from SCRUM-Japan GI-SCREEN and GOZILA
6/3

 
8 a.m. - 11 a.m. 3528
Association between gene fusions and anti-EGFR resistance signature in
colorectal cancer.
6/3
 
8 a.m. - 11 a.m. 3564
Prediction model for detecting Circulating tumor DNA (ctDNA) in
Metastatic Colorectal Cancer (mCRC).
6/3
 
8 a.m. - 11 a.m. 3590
A Landscape of Circulating Tumor DNA in Esophageal Adenocarcinoma and
Squamous Cell Carcinoma.
6/3
 
8 a.m. - 11 a.m. 4070
Blood-Based Next-Generation Sequencing Analysis of Neuroendocrine
Tumors
6/3
 
8 a.m. - 11 a.m. 4110
Circulating tumor DNA dynamics, serial testing and evolution on treatment
in 322 colorectal cancer patients.
6/3
 
8 a.m. - 11 a.m. 3566
Genomic testing and treatment landscape in patients (pts) with advanced
non-small cell lung cancer (aNSCLC) using real-world data from community
oncology practices
6/3

 
1:15 p.m. - 4:15 p.m. 1585
Correlation of circulating tumor DNA (ctDNA), tissue-based genomic
profiling and clinical efficacy in the biomarker directed Ph1b trial in
metastatic bladder cancer (BISCAY).
6/3

 
1:15 p.m. - 4:15 p.m. 4553

About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its LUNAR development programs for recurrence and early detection. Since its launch in 2014, Guardant360 has been used by more than 6,000 oncologists, over 50 biopharmaceutical companies and all 28 of the National Comprehensive Cancer Network centers.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the expected impact of data to be presented at upcoming scientific congresses. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. Additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2018 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

Investor Contact:
Lynn Lewis or Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Josh Wein or Ian Stone
press@guardanthealth.com

GHLogo2018F.png

Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.